KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV)

Group 1 - KalVista Pharmaceuticals, Inc. (KALV) shares have increased following FDA approval of its HAE therapy Ekterly, which is the first oral on-demand treatment for HAE attacks [2] - Since receiving FDA approval in July 2025, Ekterly has generated revenue for the company [2] - The Biotech Forum, led by Bret Jensen, offers a model portfolio of 12-20 high upside biotech stocks and provides market commentary and portfolio updates weekly [2]